سعر جانوفيا 50مجم 28 قرص 2025

Sitagliptin 50 mg film-coated tablets, an oral DPP-4 inhibitor for glycaemic control in adults with type 2 diabetes.

• Adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus (not for type 1 diabetes).Population: AdultsDailyMed (U.S. National Library of Medicine)

• Adverse reactions reported in at least 5% and more often than placebo in trials included nasopharyngitis, upper respiratory tract infection and headache.International label, same product · DailyMed (U.S. National Library of Medicine)

• History of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema.International label, same product · DailyMed (U.S. National Library of Medicine)

• Acute pancreatitis (including fatal haemorrhagic or necrotising) has been reported; discontinue promptly if suspected.International label, same product · DailyMed (U.S. National Library of Medicine)
• Heart failure: consider risks and benefits in patients at risk (prior heart failure, renal impairment) and monitor for symptoms.International label, same product · DailyMed (U.S. National Library of Medicine)
• Acute renal failure, sometimes requiring dialysis, has been reported; assess renal function before and during therapy.International label, same product · DailyMed (U.S. National Library of Medicine)

• Insulin and insulin secretagogues (e.g. sulfonylureas)Coadministration may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycaemia.DailyMed (U.S. National Library of Medicine)

• Limited data in pregnant women are not sufficient to inform a drug-associated risk of major birth defects or miscarriage; poorly controlled diabetes carries maternal and fetal risks. No adverse developmental effects in rats and rabbits at 30 and 20 times the clinical dose.International label, same product · DailyMed (U.S. National Library of Medicine)
• No information on presence in human milk; sitagliptin is present in rat milk (milk-to-plasma ratio 4:1). Weigh benefits of breastfeeding against the mother's need for the drug.International label, same product · DailyMed (U.S. National Library of Medicine)

• Sitagliptin: DPP-4 inhibitor that slows inactivation of the incretin hormones GLP-1 and GIP, increasing glucose-dependent insulin release and lowering glucagon.